Nicole L Mihalopoulos1, Michael G Spigarelli2. 1. Division of Adolescent Medicine, University of Utah, Salt Lake City, Utah. 2. Division of Adolescent Medicine, University of Utah, Salt Lake City, Utah; Department of Clinical Pharmacology, University of Utah, Salt Lake City, Utah.. Electronic address: clinicaltherapeuticspeds@gmail.com.
Abstract
PURPOSE: The purpose of this article is to provide a review of the existing literature for the comanagement of depression and obesity in the pediatric population. METHODS: A review of the current literature was conducted using EBSCOhost and EMBASE to identify evidence and recommendations for the comanagement of depression and obesity among children and adolescents (aged 2-18 years). Additional search criteria included peer-reviewed, English language-only full-text articles published before August 2015. FINDINGS: Multiple factors contribute to and influence the interplay of obesity and depression in the pediatric population. These 2 chronic conditions are affected by multiple factors, including the roles of the family, school, health care practitioners, and access to health care. In addition, there are no formal recommendations for the treatment of depression in the setting of obesity for pediatric or adult populations, and there is only medication approved by the Food and Drug Administration (orlistat) for the treatment of obesity in the adolescent population. Bariatric surgery may play a role in some adolescents, but larger and long-term clinical studies with the use of therapeutic agents in conjunction with lifestyle modification need to be conducted to support this. IMPLICATIONS: The interrelatedness of these 2 separate diseases is not well understood; the presence of 1 of the diseases clearly contributes to the manifestation of the other and likely to the ability to treat the other disease. Current focus is on modifying behavior to decrease weight. Weight loss is associated with improvement in depressive symptoms but may not be adequate to treat depression.
PURPOSE: The purpose of this article is to provide a review of the existing literature for the comanagement of depression and obesity in the pediatric population. METHODS: A review of the current literature was conducted using EBSCOhost and EMBASE to identify evidence and recommendations for the comanagement of depression and obesity among children and adolescents (aged 2-18 years). Additional search criteria included peer-reviewed, English language-only full-text articles published before August 2015. FINDINGS: Multiple factors contribute to and influence the interplay of obesity and depression in the pediatric population. These 2 chronic conditions are affected by multiple factors, including the roles of the family, school, health care practitioners, and access to health care. In addition, there are no formal recommendations for the treatment of depression in the setting of obesity for pediatric or adult populations, and there is only medication approved by the Food and Drug Administration (orlistat) for the treatment of obesity in the adolescent population. Bariatric surgery may play a role in some adolescents, but larger and long-term clinical studies with the use of therapeutic agents in conjunction with lifestyle modification need to be conducted to support this. IMPLICATIONS: The interrelatedness of these 2 separate diseases is not well understood; the presence of 1 of the diseases clearly contributes to the manifestation of the other and likely to the ability to treat the other disease. Current focus is on modifying behavior to decrease weight. Weight loss is associated with improvement in depressive symptoms but may not be adequate to treat depression.
Authors: Robyn Sysko; Michael J Devlin; Tom B Hildebrandt; Stephanie K Brewer; Jeffrey L Zitsman; B Timothy Walsh Journal: J Clin Psychiatry Date: 2012-10 Impact factor: 4.384
Authors: Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman Journal: Arch Gen Psychiatry Date: 2010-03
Authors: David B Allison; John W Newcomer; Andrea L Dunn; James A Blumenthal; Anthony N Fabricatore; Gail L Daumit; Mark B Cope; William T Riley; Betty Vreeland; Joseph R Hibbeln; Jonathan E Alpert Journal: Am J Prev Med Date: 2009-04 Impact factor: 5.043
Authors: George I Papakostas; Timothy Petersen; Dan V Iosifescu; Alana M Burns; Andrew A Nierenberg; Jonathan E Alpert; Jerrold F Rosenbaum; Maurizio Fava Journal: Int J Neuropsychopharmacol Date: 2004-09-13 Impact factor: 5.176